[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolism-changes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolism-changes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,72,108,149,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632581","acute-and-chronic-effects-of-obesity-100632581",false,"NCT07515547","Acute and Chronic Effects of Obesity","ACEO","Inclusion Criteria:\n\nWe are recruiting two groups of sedentary or untrained males and pre-menopausal females (age 25-40 years) with body mass indices (BMI) between 30.0-39.9 kg\u002Fm\\^2. All participants will be required to provide a medical record and\u002For photographic evidence of weight at childhood (around age of 10-17 years old). Individuals with BMI between 40.0-41.9 may be included in the case that an individual with a much shorter height falls within this range, as BMI does not always properly define obesity type. Once the participant completes their DEXA scan, we will be able to more accurately assess the participant's obesity level and re-evaluate their elgibility.\n\nExclusion criteria:\n\nParticipants will be excluded if they are pregnant or planning to become pregnant, breast-feeding, presently using nicotine containing products (e.g. cigarettes, chewing tobacco, nicotine gum etc.), taking certain anti-depressants and anti-hypertensives. More modern medications will not need to be excluded as they don't affect weight loss or weight gain. As medication use will be screened, if the participant is using medications that do not affect our outcomes they will be included in the study. Participants will also be excluded if they have had any surgery (e.g. gastric bypass, magnetic implants) or have any conditions (e.g. iron deficiency anemia) or diseases (e.g. diabetes, cancer, IBD, history of eating disorders or mental illness) that may affect immune function and thus study outcomes, or the ability to participate in the study.\n\nParticipants must also have been weight stable for at least 2 months.","ALL","25 Years","40 Years",{"count":20,"type":21},150,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this study is to understand if there are differences in the fat, muscle and metabolism of individuals who developed obesity during childhood versus those who developed obesity in adulthood. We will do this by having recruited participants undergo subcutaneous adipose tissue biopsies in the abdomen and thigh, a muscle biopsy in the thigh, collect blood and urine samples, a DEXA scan and 3 submaximal exercise tests. participants will also have their resting energy expenditure measured through indirect calorimetry to tailor a targeted weight loss protocol through caloric restriction and cardiovascular exercise (3 times a week). After 10% of weight loss is completed, study participants will repeat all tests during a 2 week weight stabilization period. At 12 weeks into the intervention, indirect calorimetry, DEXA scan and blood tests will be repeated.",[26,27,28],"Obesity & Overweight","Metabolism Changes","Lipid Metabolism","RECRUITING","2026-03-31",{"date":32,"type":33},"2026-04-07","ACTUAL",{"date":35,"type":33},"2025-04-30",{"date":37,"type":21},"2029-08",{"name":39,"class":40},"Concordia University, Montreal","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100631533","the-effects-of-daytime-nighttime-and-combined-heat-exposure-on-human-health-100631533","NCT07501923","The Effects of Daytime, Nighttime, and Combined Heat Exposure on Human Health","Randomized Controlled Crossover Trial on the Effects of Daytime, Nighttime, and Combined Heat Exposure on Human Health","Inclusion Criteria:\n\n* Age 18-30;\n* In good health, with no history of cardiovascular disease, respiratory disease, diabetes, endocrine disorders, neurological or psychiatric conditions;\n* No smoking or alcohol addiction, no history of substance abuse;\n* No prior history of particular sensitivity to high-temperature environments.\n\nExclusion Criteria:\n\n* Individuals who have experienced fever, colds, infectious diseases, or significant physical trauma within two weeks prior to the high-temperature test;\n* Individuals currently using medications that may affect psychological, cognitive, cardiovascular, or respiratory functions;\n* Pregnant women and lactating females;\n* Participants shall not be scheduled to participate during menstruation;\n* Individuals with a history of fainting or severe discomfort caused by high temperatures.",true,"18 Years","30 Years",{"count":53,"type":21},35,"INTERVENTIONAL",[56],"NA","Assess the acute effects of high-temperature exposure (including both daytime and nighttime conditions) on multiple physiological and psychological indicators, including cardiovascular, respiratory, neuropsychiatric, and metabolic functions, along with their potential mechanisms.",[27,59,60,61],"Psychology Functional Behavior","Cardiovascular System","Respiratory System","2026-03-24",{"date":64,"type":33},"2026-03-30",{"date":66,"type":33},"2025-06-01",{"date":68,"type":21},"2026-12-31",{"name":70,"class":40},"Jian Cheng",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":54,"phases":83,"briefSummary":84,"conditions":85,"keywords":96,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":71},"100618258","nighttime-synchrony-of-your-nutrition-and-circadian-health-100618258","NCT07329283","Nighttime Synchrony of Your Nutrition and Circadian Health","Nighttime Synchrony of Your Nutrition and Circadian Health: The N-Sync Study","N-Sync","Inclusion Criteria:\n\n1. Age: 18-35 years old; equal numbers of men and women\n2. Body Mass Index (BMI): 18.5-24.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) 7-9 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or apnea hypopnea index (AHI) ≥5\n2. Evidence of significant organ system dysfunction or disease (e.g., heart disease, diabetes)\n3. Fasting plasma glucose ≥100 mg\u002FdL\n4. Major psychiatric illness (e.g., major depressive disorder)\n5. Cancer that has been in remission less than 5 years\n6. History of shift-work in prior year\n7. Weight change \\>5% of body weight over prior six months\n8. Currently following a weight-loss program\n9. Menopause\n10. Pregnant\u002Fnursing\n11. Greater than 5-day variation in menstrual cycle length month-to-month\n12. Currently smoking\n13. Alcohol intake \\>14 drinks\u002Fweek or \\>3 drinks\u002Fday.\n14. Use of prescription medications (except oral contraceptives) within one month prior to or during in-lab visits.\n15. Consumption of illegal drugs or \\>500mg per day of caffeine.","35 Years",{"count":82,"type":21},120,[56],"Sleep is an important factor for overall health. This study will see how different light exposure patterns and food intake impact a person's metabolism (how the body breaks down food) when sleeping is reduced.\n\nParticipants will attend 6 to 8 in-person visits to the study clinic, including three overnight stays. People will complete surveys and medical tests. The study will last about 4 to 6 months.",[86,27,87,88,89,90,91,92,93,94,95],"Sleep","Circadian Rhythm","Lifestyle Factors","Sleep Hygiene","Sleep Hygiene, Inadequate","Sleep Deprivation","Insufficient Sleep","Circadian Misalignment","Circadian Dysregulation","Light Exposure",[86,95,97,87,98,88,89],"Metabolism","Food Intake","2026-01-20",{"date":101,"type":33},"2026-01-22",{"date":103,"type":33},"2025-12-19",{"date":105,"type":21},"2031-05-31",{"name":107,"class":40},"University of Utah",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":54,"phases":117,"briefSummary":118,"conditions":119,"keywords":126,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":71},"100612570","follow-up-study-of-varapodio-trial-effect-of-longevity-and-fasting-mimicking-diet-on-risk-factors-age-correlated-and-biomarkers-of-aging-100612570","NCT07255300","Follow up Study of Varapodio Trial: Effect of Longevity and Fasting Mimicking Diet on Risk Factors Age Correlated and Biomarkers of Aging","Follow up Study of the Effects of the Longevity and the Fasting Mimicking Diet on Body Composition, Age-related Risk Factors and Biomarkers of Aging in a Randomized Study 1 and 2","Inclusion Criteria:\n\nSubjects of 30-65 years of age;\n\nExclusion Criteria:\n\nindividuals with a family member already included in the study; individuals who are allergic to tree nuts (macadamia, cashew, almond, pecan), soy, oats, sesame, or celery\u002Fceleriac; pregnant females; Individuals with any documented cancer diagnosis within the past 5 years; documented myocardial infarction within past 5 years; documented cerebrovascular accident within past 5 years; chronic steroid use (longer than 45 consecutive days); insulin-dependent diabetes mellitus; individuals taking insulin or insulin-like drugs and individuals taking hypoglycemic agents other than metformin. In this last case, close attention will therefore be paid to the self-monitoring of blood glucose during the FMD cycles; Individuals with severe hypertension (systolic greater than 200 mmHg and or diastolic greater than 105 mmHg.\n\nChange in prescription medications, over-the-counter (OTC) medications, medical foods, and nutritional supplements within 30 days prior to the start and for the duration of the study.\n\nUse of medications classified as narcotics 15 days prior start and for the duration of the study.\n\nUse of prescription medications and\u002For over-the-counter medications for acute and semi- acute medical conditions 15 days prior to start and for the duration of the study.\n\nUse of acetaminophen is permitted on an as-needed basis. Use of an investigational drug or participation in an investigational study within 30 days prior to the start and for the duration of the study.\n\nUse of oral or injectable corticosteroids within 30 days prior to the start and for the duration of the study.\n\nUse of anticoagulant medications (heparin compounds or warfarin) within 30 days prior to the start and for the duration of the study. Use of aspirin 81 mg or 325 mg once daily is permitted.\n\nUse of neuroactive prescription medications including major and atypical antipsychotic medications, anti-depressants, anti-anxiolytics, and epilepsy medications within 30 days prior to the start and for the duration of the study.\n\n(subjects will not be allowed to discontinue prohibited prescription medications to meet enrolment criteria).\n\nA history of allergy or intolerance to study products. Detailed descriptions of study product are included in Section 4.1 and 4.2, appended to the Study Informed Consent.\n\nClinically significant vital sign abnormalities (systolic blood pressure \\\u003C90 mmHg or \\>200 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>105 mmHg or resting heart rate of \\\u003C50 or \\>100 bpm) at screening visit.\n\nA serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease.\n\nKnown infection with HIV, TB or Hepatitis B or C.\n\nA current diagnosis or personal history of:\n\nAny cardiovascular disease including myocardial infarction, angina, cardiovascular surgery (within 5 years), congestive heart failure, cardiac arrhythmias or conduction abnormalities, cerebrovascular accident, transient ischemic attack (TIA), or peripheral vascular disease, deep vein thrombosis or pulmonary embolus. Diabetes mellitus requiring inhaled or injected insulin.\n\nAny autoimmune disease such as inflammatory bowel disease (including Crohn's disease and\u002For ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and\u002For thyroiditis.\n\nAny significant liver or kidney disease such as cirrhosis or non-alcoholic fatty liver disease, glomerulonephritis, and\u002For ongoing dialysis treatment.\n\nAny malignancy (with the exception of adequately treated malignancies with no known recurrence for \\>2 years).\n\nAny serious mental illness including a history of attempted suicide. Any medical condition that in the opinion of the primary care doctor or a specialist would preclude safe participation in this study or interfere with compliance.\n\nUse of drugs of abuse (such as marijuana, cocaine, phencyclidine \\[PCP\\] and methamphetamine) 15 days prior to Day 1 and for the duration of the study.\n\nHistory of regular intake of \\>14 alcoholic drinks per week for females, and \\>21 drinks per week for males (1 drink = 35 cl. beer, 12 cl. wine, or 30 ml. hard liquor).\n\nTechnical reasons\n\nAny condition in which bioelectrical impedance testing would be impossible or uninterpretable (e.g. prostheses in extremities on both sides, limb amputation, implanted pacemaker, inability to lay still or supine, or skin defects on preferred electrode placement sites.\n\nOther Exclusion Criteria: Inability to comply with study and\u002For follow-up visits.\n\nAny concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAny sound medical, psychiatric and\u002For social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAbnormal laboratory findings including: abnormal blood counts (hematocrit \\\u003C 33% or \\> 47%; WBC \\\u003C 3.0 or \\> 12.0 x10\\^3\u002Fmm3; platelets \\\u003C 140 or \\> 500 x 10\\^9\u002FL); abnormal kidney function test (creatinine \\> 2.5 mg\u002FdL) or liver function test(s) (AST, ALT, alkaline phosphatase) \\> 1.5X the upper limit of normal; serum calcium \\> 11 mg\u002FdL); serum K \\\u003C 3.5 mEq\u002FL; Na \\\u003C 134 or \\> 148 mmolL-1 Women of Childbearing Potential Contraception: the effects of the study products on the developing human fetus have not been studied extensively. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential will have a pregnancy test prior to receiving study products. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.\n\nPregnancy: because there is an unknown but potential risk for adverse events in pregnant women during treatment with the study products, pregnant women are not eligible for study participation.\n\nBreast-feeding: Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study products, breastfeeding mothers are not eligible for study participation.",{"count":116,"type":21},135,[56],"A large ongoing randomized, open-label trial aimed at evaluating the effects of two different dietary interventions, FMD and LD, on body composition and cardiovascular (CV) biomarkers in a real word population (NCT05698654) is actually ongoing. This trial started in January 2024 will enrol 501 adult subjects between the ages of 30 and 65: 167 subjects randomized to the FMD arm with a 5-day meal program once every three months for a 6-month period (arm 1); 167 subjects randomized to follow the FMD plus a Longevity Diet program (FMD+LD) for a 6-month period (arm 2); 167 randomized to the control group (arm 3) that will continue their usual diet. On 2024,410, participants were enrolled and randomly assigned to FMD, FMD + LD, or control arm. Although preliminary data demonstrated the beneficial effects of such nutritional plans on body weight, BMI, body composition, and cardiovascular (CV) biomarkers, limited data is available on the long-term effects of these powerful nutritional interventions.",[120,121,122,27,123,124,125],"Fat Mass","Risk Factors Cardiovascular Disease","Epigenetic Aging","Overweight (BMI > 25)","Risk Behavior","Obesity (Disorder)",[127,128,129,130,131,132,133,134,135,136,137,138,139,120],"fasting","fasting mimicking diet","Longevity Diet","Longevity","Diet","Aging","FMD","Nutrition","Diseases","LD","Clinical Trial","Randomized","Health","2025-11-20",{"date":142,"type":33},"2025-12-01",{"date":144,"type":33},"2025-05-02",{"date":146,"type":21},"2027-06-02",{"name":148,"class":40},"Fondazione Valter Longo",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":54,"phases":159,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":71},"100579382","anti-hypertensive-therapy-and-exercise-treatment-to-improve-vascular-health-in-patients-with-hypertension-100579382","NCT06823570","Anti-hypertensive Therapy and Exercise Treatment to Improve Vascular Health in Patients With Hypertension.","Anti-hypertensive Therapy and Exercise Treatment to Improve Vascular Health in Patients With Hypertension. A Randomized Controlled Trial.","Antitension","Inclusion Criteria:\n\n\\- systolic hypertension grade I-II (BP values \\>140 mmHg to \\\u003C180 mmHg) without anti-hypertensive medication treatment\n\nExclusion Criteria:\n\n* no written informed consent\n* age \\\u003C18 years\n* isolated diastolic hypertension\n* medical contraindications for the exercise treatment (for example orthopedic problems or an abnormal ECG during the cardio respiratory exercise test)\n* chronic eye diseases on both eyes (for example macular degeneration or glaucoma) or high intraocular pressure (\\>20 mmHg)",{"count":158,"type":21},60,[56],"This is a prospective, monocentric, randomized controlled trial to investigate the effect of anti-hypertensive treatment and\u002For individualized exercise training intervention on blood pressure and vascular health. Furthermore the investigators want to decipher mechanisms, which contribute to vascular health by analyzing changes in metabolism and cell function in relation to vascular reaction.",[162,163,164,27],"Hypertension","Vascular Function","Fitness Testing",[166,167,168,169,170],"cardiorespiratory fitness","retinal microcirculation","endothelial function","exercise training","lifestyle treatment","2025-03-11",{"date":173,"type":33},"2025-03-12",{"date":175,"type":21},"2025-04-01",{"date":177,"type":21},"2028-12-31",{"name":179,"class":40},"Heinrich-Heine University, Duesseldorf",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":191,"conditions":192,"keywords":196,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":71},"100574085","evaluation-of-blood-protein-o-glcnacylation-levels-in-children-100574085","NCT06754696","Evaluation of Blood Protein O-GlcNAcylation Levels in Children","Evaluation of Blood Protein O-GlcNAcylation Levels in Children - CHANCE Study (Child Heart O-glcnAc Nantes)","CHANCE","1. Healthy group\n\n   Inclusion Criteria :\n   * Age from 0 to 17 years at the time of sampling (including premature infants)\n   * Children coming to hospital for a blood sample to be taken as part of a pre-operative check-up, an allergy check-up or a check-up as part of a pathology other than sepsis.\n   * Premature infants benefiting from a blood sample as part of their monitoring and management of prematurity\n   * Collection of umbilical cord blood\n   * Signed consent\n\n   Exclusion Criteria :\n   * Children with an infection\n   * Children with fever\n   * Children with an immune deficiency\n   * Children with autoimmune disease\n   * Children with metabolic disease\n   * Children with haematological diseases\n   * Children with a genetic disease\n   * Unsigned consent\n   * Refusal by parents or child\n2. Septic group\n\nInclusion Criteria :\n\n* Age from 0 to 17 years at the time of sampling (including preterm infants)\n* Children with suspected sepsis or diagnosed sepsis according to the 2016 definition\n* Premature infants having blood drawn for suspected or diagnosed sepsis\n* All responsible bacteria, viruses or fungi\n* Signed bio-collection consent\n\nExclusion Criteria :\n\n* Children with an immune deficiency\n* Children with autoimmune disease\n* Children with a metabolic disease\n* Children with haematological diseases\n* Children with a genetic disease\n* Unsigned bio-collection consent\n* Refusal by parents or child","17 Years",{"count":190,"type":21},240,"Stimulation of O-GlcNAcylation has been shown to be beneficial in several acute pathologies and different animal models, such as haemorrhagic and septic shock, and ischaemia-reperfusion (cerebral and cardiac). It could therefore be interesting to use this approach in children in order to limit the impact of various pathologies inducing SIRS, such as extracorporeal circulation for major surgery, septic shock or various traumas. The investigators demonstrated in 2 different animal models (endotoxemia by injection of Lipopolysaccharides and caecal puncture ligation model) with 3 different pharmacological molecules (Glucosamine, ThiametG and NButGT) that stimulation of O-GlcNAcylation was beneficial in the early phase of septic shock with a marked effect on cardiac function and survival. The investigators thus demonstrated that stimulation of O-GlcNAcylation was beneficial in young rats in septic shock. However, none of this work has yet been reproduced in humans, either children or adults.",[193,194,195,27],"Sepsis","Septic Shock","Development and Health",[197,193,198,199,200],"O-GlcNAcylation","Septic shock","metabolism","children","2025-02-11",{"date":203,"type":33},"2025-02-13",{"date":205,"type":33},"2025-01-30",{"date":207,"type":21},"2036-01-31",{"name":209,"class":40},"Nantes University Hospital"]